Russell Pachynski, MD

Medical Oncologist

Primary Academic Title

Associate Professor of Medicine, Division of Medical Oncology, Director of GU Oncology Research, WashU Medicine

Clinical Expertise

As a member of our kidney, bladder and prostate cancer specialist teams, Dr. Pachynski cares for patients diagnosed with these cancers through treatment and recovery.

Research Interest

My clinical specialty is genitourinary cancers, with a focus on prostate cancer. I also maintain an active lab focusing on leukocyte trafficking and its role in tumor immunology, with the ultimate goal of advantageously controlling this for patients’ benefits. I hope to advance translational immunotherapy and be able to bring novel therapies from the bench to the bedside, and back again.

Education

2003: MD, University of Wisconsin-Madison Medical School

Training

2003 - 2006: Resident, internal medicine, Stanford University Medical Center, Stanford, Calif.
2006 - 2010: Fellow, oncology, Stanford University

Board Certification

2007: American Board of Internal Medicine
2017: American Board of Internal Medicine- medical oncology

Selected Research Publications

Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic.

Somani VK, Zhang X, Chen TH, [...] Pachynski RK, [...] Lim KH
Mol Cancer 2026

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer.

Rawat K, Punia V, Mathews P, [...] Pachynski RK
J Immunother Cancer 2025

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

Einstein DJ, Abel ML, Aragon-Ching JB, [...] Pachynski RK, [...] Madan RA
J Clin Oncol 2025

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

Luke JJ, Gelmon K, Siu LL, [...] Pachynski RK, [...] Tabernero J
Clin Cancer Res 2025

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Petrylak DP, Ratta R, Matsubara N, [...] Pachynski R, [...] Fizazi K
J Clin Oncol 2025

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.

Sweis RF, Chatta GS, Jain RK, [...] Pachynski RK, Yu EY
Clin Cancer Res 2025

Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer.

Chauhan PS, Alahi I, Sinha S, [...] Pachynski RK, [...] Chaudhuri AA
Clin Cancer Res 2025

Tumour evolution and microenvironment interactions in 2D and 3D space.

Mo CK, Liu J, Chen S, [...] Pachynski R, [...] Ding L
Nature 2024

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Nguyen CB, Reimers MA, Perera C, [...] Pachynski RK, [...] Alva AS
Clin Cancer Res 2024

High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance.

Saeed MA, Peng B, Kim K, [...] Pachynski RK
Cancer Immunol Res 2024

Epigenetic regulation during cancer transitions across 11 tumour types.

Terekhanova NV, Karpova A, Liang WW, [...] Pachynski R, [...] Ding L
Nature 2023

Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.

Sridaran D, Bradshaw E, DeSelm C, Pachynski R, [...] Mahajan NP
Cell Rep Med 2023

Chemerin triggers migration of a CD8 T cell subset with natural killer cell functions.

Ballet R, LaJevic M, Huskey-Mullin N, [...] Pachynski RK, [...] Zabel BA
Mol Ther 2023